EBS Q4 2019 Earnings — Emergent BioSolutions Inc. Revenue & Financial Results | Market Cap Arena

EBSEmergent BioSolutions Inc.

$433M

Q4 2019 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$336M+24.2% YoY

Gross Profit

$203M60.5% margin

Operating Income

$78M23.1% margin

Net Income

$47M14.0% margin

EPS (Diluted)

$0.89

QoQ Revenue Growth

+7.8%

Cash Flow

Operating Cash Flow

$122M

Free Cash Flow

$86M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$2.3B

Total Liabilities

$1.2B

Stockholders' Equity

$1.1B

Cash & Equivalents

$168M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$336M	$271M	+24.2%
Gross Profit	$203M	$108M	+87.8%
Operating Income	$78M	$11M	+593.8%
Net Income	$47M	-$4M	+1440.0%

Revenue Segments

Product

$311M86%

Contract Development And Manufacturing

$25M7%

Contracts and Grants

$24M7%

Geographic Segments

UNITED STATES

$242M67%

Non-US

$118M33%